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For breast cancer hereditary syndrome, 2 major susceptibility
genes have been cloned, BRCA1 (Miki et al, 1994) and BRCA2
(Wooster et al, 1995; Tavtigian et al, 1996), and additional but as
yet unidentified genes are suspected to be involved (Serova et al,
1997). The contribution of mutations in BRCA1 and BRCA2 genes
to the population incidence of inherited breast cancer has been
described (Shattuck-Eidens et al, 1997; Ford et al, 1998; Hartge 
et al, 1999), yet estimates are still inconclusive due to the
complexity of analysis of large-sized genes without hot-spots for
sequence variation and to the substantial number of samples
required to obtain reliable estimates. Intensive mutation analyses
have been conducted on BRCA genes using different techniques
and have led to the identification of more than 200 mutations, scat-
tered throughout the genes. Complete direct sequencing assures
the highest sensitivity, but is laborious and time-consuming, also
considering the genomic structure and size of the genes, so that
less sensitive pre-screening scanning methods, such as SSCP
(Friedman et al, 1994), DGGE (Stoppa-Lyonnet et al, 1997), and
PTT (Hogervorst et al, 1995) are commonly used. 
In order to provide a more feasible and less expensive test for
mutation screening prior to sequencing, we evaluated the potential
of Cleavase Fragment Length Polymorphism method (CFLP;
Third Wave Technologies, Madison, WI), reported as capable of
detecting single and multiple base alterations in fragments up to 2
kb in length (Brow et al, 1996). CFLP scanning method uses an
endonuclease-based approach to detect sequence alterations in
DNA samples. An engineered structure-specific endonuclease, the
Cleavase I enzyme, recognises and cleaves the 5′ end of secondary
structures (i.e. stem-loops) that form when thermally denatured
DNA strands are cooled, at the junction between single-stranded
and double-stranded DNA. Digestion results in a collection of
fragments that is unique to a specific DNA strand. Changes in the
sequence of that strand, such as single point mutations, insertions,
or deletions, will alter the secondary structures formed and the
CFLP pattern detected. To date the CFLP method has been used 
in the differentiation of microbial species (Brow et al, 1996),
hepatitis C virus genotyping (Marshall et al, 1997; Sreevatsan 
et al, 1998) and has been offered as an alternative to SSCP
(Maddox et al, 1997; Rosetti et al, 1997), HA (Rosetti et al, 1997)
and DGGE (Eisinger et al, 1998) analysis for mutation scanning. 
We developed a DNA analysis procedure based on fluorescent
dNTP incorporation, Cleavase I endonuclease digestion and
simultaneous, multiple fragment detection, by combining the
CFLP procedure with the GeneScan software, and called it
Multiple-Dye CFLP (MD-CFLP). By incorporating different
internal labelling and allowing for the size of the test fragment, it
is possible to analyse patterns corresponding to the four different
BRCA1 amplicons loaded on a single lane of a denaturing poly-
acrylamide gel. 
MATERIAL AND METHODS 
Case series 
We analysed a first sample panel of 30 patients with familial breast
and/or ovarian cancer. 27 samples came from patients enrolled in
an international multicentric study involving institutions from
Italy, Finland, Germany, Switzerland and the United States
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BJOC 01-1988 845-849  10/9/01  1:53 pm  Page 845(Shattuck-Eidens et al, 1997) and were provided by the Division of
Medical Oncology/Pierantoni Hospital (Forlì, Italy). 3 samples
were provided by the ‘Istituto Nazionale Tumori’ (INT; Milan,
Italy). 
A second sample panel of 21 patients was further used for blind
MD-CFLP analysis and was provided by the ‘Istituto Nazionale
Tumori’ (INT; Milan, Italy). 
DNA preparation and PCR amplification 
DNA was isolated from peripheral blood lymphocytes by standard
phenol/chloroform procedure. Exons 11 and 16 of BRCA1 were
PCR-amplified from samples containing a sequence alteration,
mutation or polymorphism within each exon, as well as from wild-
type samples. Exon 11, which spans over half of the gene (3426
bp), was divided into 3 partially overlapping fragments, including
flanking intronic regions, for MD-CFLP analysis (Table 1): frag-
ment A, 1399 bp, spanning the flanking upstream intron and the
5′ -terminus of exon 11; fragment B, 1221 bp, covering the central
portion of the exon; and fragment C, spanning the 3′ -terminus and
the flanking downstream intron. Exon 16, with its flanking
intronic regions, 415 bp, was amplified as a single fragment due to
its relatively small dimension. PCR mixtures contained 100 ng of
DNA, 2 U of Takara ex Taq polymerase (Takara Shuzo, Co.,
Shiga, Japan), 0.2 mM of each dNTP, 10 pmol of each primer
(Table 1), and 0.5 µ M [R110] or [R6G] dUTP or 2 µ M [TAMRA]
dUTP (Perkin-Elmer, Foster City, CA) in 50 µ l of 2 mM Tris-HCl
(pH 8.0), 10 mM KCl, 2 mM Mg2+, 0.01 mM EDTA, 0.1 mM
DTT, 0.05% Tween-20, 0.05% Nonidet P-40, 5% glycerol. After
initial denaturation for 2 min at 94˚C, 40 cycles were performed
with denaturation at 94˚C for 1 min, annealing at 58˚C for 90 s,
and extension at 72˚C for 1 min. A final extension step of 5 min at
72˚C was added. The fragments were labelled by incorporation of
distinct fluorescent dUTPs during PCR amplification. Labelling
was always performed using the same dye with respect to a
specific fragment to avoid variability in DNA structure due to
incorporation of fluorescent dUTP instead of the normal thymi-
dine. PCR products were precipitated in 2 M ammonium acetate
and isopropanol for 10 min at room temperature and washed with
70% ethanol to remove unincorporated primers, labelled dUTP
and salts that could affect Cleavase I activity and double-strand -
reannealing. Better yields were obtained adding 1 µ l (20 µ g) of
glycogen prior to precipitation (Boehringer Mannheim). Dried
pellets were resuspended in 20 µ l of sterile, distilled water.
Concentration of PCR products was estimated by agarose gel elec-
trophoresis and ethidium bromide staining. 
MD-CFLP analysis 
For each MD-CFLP reaction, 200 – 400 ng of internally labelled
PCR product were diluted in distilled water in a final reaction
volume of 20 µ l. Samples were heat-denatured for 30 s at 94˚C,
quickly cooled down to the amplicon-specific reaction tempera-
tures (Table 1) to allow secondary structure formation, and mixed
with preheated enzyme mixture containing 25 U of Cleavase I
enzyme (Third Wave Technologies, Madison, WI) and 0.25 mM
MnCl2 in 5.5 µ l of 10 mM MOPS (pH 7.5), 0.05% Tween-20,
0.05% Nonidet P-40. Digestion temperatures for each amplicon
were optimised at the values reported in Table 1 at scalar tempera-
tures ranging from 40˚C to 60˚C by 5˚C or 2.5˚C increments. The
digestion by Cleavase I was allowed for 15 min and stopped by the
addition of 10 µ l stop solution (95% deionised formamide, 10 mM
EDTA and 0.05% blue dextran; SIGMA). Aliquots of the cleavage
reaction were loaded onto a 5% w/v denaturing polyacrylamide
gel (acrilamyde:bisaclylamide, 19:1, 7 M urea, 1 × TBE). Electro-
phoresis was carried out on an Applied Biosystems 373A DNA
Sequencer (Applied Biosystems, Foster City, CA) equipped with
GeneScan 672 Collection and Analysis software, and filter set A.
Electrophoresis conditions were 560 V, 20 mA and 30 W constant
power at a constant temperature of 40˚C for 12 hours. 
DNA sequence analysis 
After a second independent CFLP analysis, samples exhibiting
altered MD-CFLP patterns were confirmed by and sequenced on
an Applied Biosystem 373A DNA Sequencer using internal
primers and PRISM Dye Terminator Cycle Sequencing kit
(Perkin-Elmer) according to the manufacturer’s instructions. 
RESULTS 
Overview of MD-CFLP and multiplex array 
We used Cleavase I digestion to generate a collection of fragments
representing the unique DNA fingerprints of the test samples. We
selected test samples harbouring small changes in the DNA
sequence such as single-point mutations, insertions or deletions to
be compared with wild-type samples. We combined Cleavase I
digestion with differential internal labelling by fluorescent dUTP
incorporation, and a simultaneous, multiple fragment detection by
means of GeneScan software. The target sequence was amplified
in a single PCR reaction containing an optimised dNTP mix and a
limiting amount of fluorescent dUTP and digested by Cleavase I
enzyme. Optimal conditions were defined by comparison of 
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Table 1 BRCA1 primers and conditions for multiple-dye CFLP reactions 
Fragment Primer Primer sequence (5′→ 3′ ) Size (bp) Dye (dUTP) Cleavase reaction 
exon 11 
A BR1 E11A 5′ CCT CCA AGG TGT ATG AAG TA 1399 [R110] 50˚C/15 min 
BR1 E11A 3′ TGC TGT GCC TGA CTG GCA TT 
B BR1 E11B 5′ GCG CTT GAA CTA GTA GTC AG 1221 [R6G] 55˚C/15 min 
BR1 E11B 3′ ACG GCT AAT TGT GCT CAC TG 
C BR1 E11C 5′ GGA ACA TTC AAT GTC ACC TG 1122 [TAMRA] 52.5˚C/15 min 
BR1 E11C 3′ AAT AGA CTG GGG CAA ACA CA 
exon 16 
BR1 E16 5′ ACA GAG ACC AGA ACT TTG TA 415 [TAMRA] 42.5˚C/15 min 
BR1 E16 3′ CTT AGT CAT TAG GGA GAT AC 
BJOC 01-1988 845-849  10/9/01  1:53 pm  Page 846wild-type and altered patterns of corresponding fragments with
regard to good pattern complexity and even distribution of peaks,
avoiding sample over-digestion. Once the best MD-CFLP condi-
tions were established for each amplicon and the pattern repro-
ducibility verified, the banding pattern resulting from Cleavase
digestion was visualised on an Applied Biosystems 373A DNA
Sequencer. By adapting custom matrices to GeneScan software,
we accurately attributed signal intensity to specific fluorochromes
and subtracted the background noise caused by interfering signals.
Multiple loading was determined according to minimal overlap-
ping between migration distances of amplicons labelled with the
same dye. 
MD-CFLP patterns of the 4 differently labelled BRCA1 ampli-
cons were analysed in single and multiplex array. Comparison of
the resulting electropherograms showed no interference between
differently labelled samples loaded onto the same lane with respect
to single-lane loaded samples on the same gel (data not shown). 
DNA sequencing of wild-type and mutated BRCA1
samples 
A complete sequence analysis of the BRCA1 coding sequence and
flanking intronic regions was performed on 30 DNA samples as
described previously. 35 amplicons were developed for BRCA1
sequencing. 12 sequence variants were detected in exons 11 and 16
including 3 deleterious mutations, 2 variants of uncertain signifi-
cance and 7 common polymorphisms. The 3 deleterious alterations
were frame-shift mutations due to single- or double-nucleotide
insertions/deletions. One of the two uncertain variants identified,
corresponding to a base substitution in the intronic region between
exons 11 and 12, had never been reported before. Polymorphic
sites 2201C/T, 2430T/C, P871L, E1038G, and K1138R in exon 11
and S1613G in exon 16 were associated in 11 (36%) of the
samples analysed, giving a wild-type phenotype. Polymorphism
Q356R was independently detected in 2 samples. None of the
mutations or unclassified variants were associated with poly-
morphisms in this sample panel. 
MD-CFLP analysis of BRCA1 samples 
Of the 120 PCR products analysed by the MD-CFLP method (4
fragments for each of the 30 samples), 73 contained sequence
alterations. Corresponding sequencing data are reported. Three
deleterious mutations, 2 uncertain variants, and 68 common
polymorphisms were identified (Table 2). Thus, both sensitivity 
and specificity of MD-CFLP analysis in detecting mutations 
were 100%. Samples harbouring sequence alterations gave rise 
to unique reproducible fingerprints easily distinguishable from 
the corresponding wild-type and identifiable as variants.
Polymorphisms were always associated with reproducible peaks in
the digestion patterns. Representative electropherograms are
reported in Figure 1. Complete electropherograms representing
exon 11 and exon 16 digestion patterns of 2 samples harbouring
sequence alterations and a sample exhibiting the wild-type
sequence, as they result from multiple fragment analysis, are
illustrated in Figure 1A. 
Exon 11/fragment B detailed electropherogram of a sample
containing 3 single-nucleotide polymorphisms, compared with the
corresponding wild-type sequence, is illustrated in Figure 1B.
PCR-amplified fragments were internally labelled with R6G
fluorescent dye. Because of the internal labelling, we were able to
detect all possible products that originated from the digestion.
Since Cleavase I digestion is sequence-specific, the appearance or
disappearance of peaks in the MD-CFLP pattern revealed the pres-
ence of alterations in the given sequence compared to the wild-
type. Major deviations from the standard pattern were detected in
the central portion of the electropherogram, where 3 novel peaks
rose up. A reduction or increase in peak intensities was observed in
at least 3 sites along the pattern. 
Exon 11/fragment C MD-CFLP pattern from a sample with a
base substitution in the intron downstream exon 11 compared with
a wild-type sequence is shown in Figure 1C. PCR-amplified frag-
ments were internally labelled with TAMRA fluorescent dye. In
this instance, the sequences of the mutated and wild-type fragments
differed only in terms of a single nucleotide change, yet several
changes were found in their fingerprints. Variation of intensity was
evident in 3 peaks in the left portion of the electropherogram and in
1 in the right portion. These electropherograms highlighted a clear
distinction between wild-type and altered samples. 
Sensitivity of MD-CFLP patterns 
To assess the sensitivity of the fingerprints originated by MD-
CFLP, we examined a random panel of 21 DNA samples kindly
BRCA1 analysis in high-risk patients by Multiple-Dye CFLP 847
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Table 2 BRCA1 mutations and common polymorphisms utilised for multiple-dye CFLP set-up 
Fragment Designationa Sequence modification Type of alterationb Number of samples 
11A 916delTT delete TT F 1 
11A Q356R A→ GP 2  
11A 1499insA insert A F 1 
11A S645Y C→ AU V 1  
11B 2201C/T C→ TP1 1  
11B 2430T/C T→ CP1 1  
11B P871L C→ TP1 1  
11C E1038G A→ GP1 1  
11C 3345delAG delete AG F 1 
11C K1183R A→ GP1 1  
11C IVS11+8c A→ GU V 1  
16 S1613G A→ GP1 1  
aDesignations as reported in the Breast Cancer Information Core database (BIC) at
www.nhgri.nih.gov/Intramural_research/Lab_transfer/Bic. bF = frameshift mutation; P = polymorphism;
UV = unclassified variant. cNot previously reported. 
BJOC 01-1988 845-849  10/9/01  1:53 pm  Page 847provided by the INT (Milan, Italy) whose sequence characterisa-
tion was unknown to us. By means of MD-CFLP analysis and
further ascertainment by direct sequencing we were able to
correctly characterise 79 of the 84 fragments analysed and 8 of the
10 mutations present in the sample panel. Prior to sequencing,
each sample was submitted to 2 MD-CFLP analyses: a 100%
consistency was observed. The 84 PCR products were screened by
the MD-CFLP method (4 fragments for each of the 21 samples), as
described earlier. Of the 13 rare alterations identified, 8 corre-
sponded to known variants and 5 did not correspond to any alter-
ation of the test sequences: 4 alterations in fragment A, 1 in
fragment B, 3 in fragment C of exon 11 were correctly identified;
2 alterations in fragment A, 2 in fragment C of exon 11 and 1 in
exon 16 turned out to be false positives (Table 3). Fragments
showing altered MD-CFLP patterns were verified by direct
sequencing. The specificity of the MD-CFLP analysis in this blind
sample panel was 94%. We further compared our final data with
the sample characterisation reported by the INT and found that 2
mutations consisting of single-base substitutions in exon 11/frag-
ment B and fragment C had been missed, namely the missense
mutations R841W and 3159A/G. Thus, the sensitivity of the MD-
CFLP analysis in this sample panel was 80%. 
Common sequence variants corresponding to polymorphisms
were identified according to pattern variation frequency in 9 of the
21 samples in the panel. Polymorphisms 2201C/T, 2430T/C,
P871L, E1038G and K1183R were characterised with 100% sensi-
tivity by subsequent sequence investigation. Moreover, in 5 cases,
polymorphisms were associated with rare sequence variants
(1100delAT, 1221G > T, 1806C >T, 3159A > G and 3372insA). 
DISCUSSION 
Recent findings in the field of cancer genetics have opened the
way to molecular tests to identify high-risk patients carrying a
mutation in a cancer-predisposing gene. The use of these tests is
still controversial for ethical, psychological and social reasons, in
addition to their still undefined role in prevention and early diag-
nosis strategies (Ponder, 1997). However, it is becoming increas-
ingly important to develop methods of analysis that are highly
sensitive, have a high throughput, and are specific and accessible
in terms of time and costs (Sidransky, 1997). An accurate defini-
tion of their reliability and limits is thus necessary in order to
correctly evaluate the laboratory data impact on global patient
management. 
Although sequencing technology has seen a marked improve-
ment in recent years in terms of throughput and reliability, it
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Figure 1A MD-CFLP complete electropherograms. Sample 1: presence of
polymorphisms in exon 16 (S1613G), and in exon 11 fragment B (2201C/T,
2430T/C, P871L) and C (E1038G, K1183R). Sample 2: sequence variant
due to a base substitution in the intronic region downstream exon 11.
Control: electropherogram of a wild-type sequence. Digestion patterns
corresponding to fragments A (blue), B (green), and C (black) of exon 11 and
exon 16 (black) are represented and sites of pattern variations are indicated
with coloured arrows. All fragments were labelled as reported in Section 2.2 
Figure 1B Electropherogram details exon 11 fragment B. Comparison
between sample 1 harbouring three common polymorphisms (2201C/T,
2430T/C, P871L) and the control. Main differences are indicated with arrows 
Figure 1C Electropherogram details of exon 11 fragment C. Comparison
between sample 2 carrying a base substitution in the intronic region
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where different mutations are scattered throughout the sequence. A
good scanning technique should be much cheaper and less labour-
intensive than sequencing. There is not one technique that is over-
whelmingly preferred over the others. Factors that we considered in
the selection of the MD-CFLP mutation scanning technique are as
follows: (i) the size of the gene of interest; (ii) the high throughput
vs low throughput; (iii) the degree of sensitivity and specificity
required; and (iv) the cost of and time required for analysis. 
We developed a DNA analysis procedure based on fluorescent
dNTP incorporation, Cleavase I endonuclease digestion and simul-
taneous, multiple fragment detection, which we called Multiple-
Dye CFLP. We defined the best conditions in terms of PCR
amplification and temperature of digestion for a rapid prescreening
mutation analysis capable of ensuring a sensitivity and specificity
higher than 90%. Internal labelling increases the sensitivity of the
method and hence the detection of all the reaction products is
possible despite their size and relative intensity. This approach
allows a simultaneous check of both strands without the need for
separate single-strand reactions, which is important because some
alterations can affect the MD-CFLP pattern of one strand more
than that of the complementary one (Brow et al, 1996). The avail-
ability of GeneScan software permits the analysis of complex
electropherograms originated by internal labelling. Thus,
Multiple-Dye CFLP enables the simultaneous analysis of nearly
70% of BRCAI in a single lane of a polyacrylamide gel and speeds
up the detection of sequence alterations in large numbers of DNA
samples. Moreover, polymorphisms can be recognised on the basis
of specific fingerprints, thus limiting sequence characterisation to
variants of pathological or still unknown significance. For these
reasons we are confident that this approach will be of impact in
genetic testing for cancer susceptibility, especially when several
genes are to be investigated in one syndrome. 
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Table 3 BRCA1 blind samples analysed by multiple-dye CFLP 
Sample Analysed fragments Sequence modification Designationa Altered fragment 
11A 11B 11C 16 
1+ –– – delete AT 1100delAT 11A 
2+ –– – delete A 1206delA 11A 
3+ –– – G→ T 1221G > Tb 11A 
4+ –– – C→ T Q563X 11A 
5 – + –– delete TCAA 2846del4 11B 
6 –– + – insert A 3373insA 11C 
7 –– + – C→ T 3522C > Tb 11C 
8 –– + – G→ T 4023G > Tb 11C 
9 –– + – C→ T R841W 11B 
10 –– – +A → G 3159A > Gb 11C 
11 + –– – none wt none 
12 + –– – none wt none 
13 –– + – none wt none 
aDesignations as reported in the Breast Cancer Information Core database (BIC) at 
ww.nhgri.nih.gov/Intramural_research/Lab_transfer/Bic.  bNot previously reported. 
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